BIO-RAD PLATELIA TOXO IGG TMB
Device Facts
| Record ID | K013839 |
|---|---|
| Device Name | BIO-RAD PLATELIA TOXO IGG TMB |
| Applicant | Bio-Rad |
| Product Code | LGD · Microbiology |
| Decision Date | Sep 30, 2002 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.3780 |
| Device Class | Class 2 |
| Attributes | Real-World Evidence |
Real-World Evidence
| Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags |
|---|---|---|---|---|---|
| K013839 · Sep 30, 2002 | BIO-RAD PLATELIA TOXO IGG TMB | Bio-Rad | Retrospective seroconversion panels; Routine clinical laboratory samples from pregnant women | Retrospective clinical specimens were used to evaluate the performance of the Platelia Toxo IgG TMB assay compared to a predicate device and to establish expected values in a clinical population. | Retrospective study; Routine clinical laboratory data; Seroconversion panels |
Clinical Evidence
| Study Design | Population | Comparator | Key Endpoints |
|---|---|---|---|
| Comparison Study; Retrospective analysis of seroconversion panels and prospective clinical samples | Pregnant women and individuals in seroconversion; Sample Size: 503 | Commercially available enzyme immunoassay (EIA) | Negative, positive, and overall agreement |
| Expected Values Study; Observational cohort | Pregnant women; Sample Size: 503 | Not applicable for this study | Distribution of IU/ml values |
Indications for Use
The Platelia® Toxo IgG TMB kit is an in-vitro diagnostic test kit for the qualitative and quantitative detection of anti-Toxoplasma gondii IgG in human serum or plasma (EDTA, Heparin, Citrate). Note: The Platelia® Toxo IgG TMB assay has not been cleared/approved by the FDA for blood/plasma donor screening.
Device Story
Indirect ELISA assay for detection of anti-Toxoplasma gondii IgG antibodies in human serum or plasma. Samples added to T. gondii antigen-coated microplate wells; incubation allows antibody binding. Unbound proteins washed away; peroxidase-labeled monoclonal antibody conjugate added. Second incubation binds conjugate to IgG-antigen complexes. Unbound conjugate washed away. Peroxidase substrate and TMB chromogen added to initiate color reaction; reaction stopped with acid. Optical density measured via spectrophotometer at 450nm. Result converted to IU/ml using standard curve calibrated against WHO standard (TOXM185). Used in clinical laboratory settings by trained personnel. Output assists clinicians in assessing Toxoplasma gondii infection status.
Clinical Evidence
Bench testing only. Precision studies (intra-assay and inter-assay) performed across three sites using serum and plasma (EDTA, Heparin, Citrate) samples. Comparison study of 503 samples (468 prospective, 35 retrospective) against another commercial EIA showed 99.71% negative agreement, 100% positive agreement, and 99.80% overall agreement. CDC serum panel (70 positive, 30 negative) showed 100% agreement with both positive and negative specimens.
Technological Characteristics
96-well breakaway microplate EIA. Indirect ELISA principle. Peroxidase-labeled monoclonal antibody conjugate. TMB chromogen solution. Dual wavelength spectrophotometric detection at 450nm and 620nm. Standard curve calibration against WHO standard (TOXM185).
Indications for Use
Indicated for qualitative and quantitative detection of anti-Toxoplasma gondii IgG in human serum or plasma (EDTA, Heparin, Citrate). Not for blood/plasma donor screening.
Regulatory Classification
Identification
Toxoplasma gondii serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Toxoplasma gondii in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify Toxoplasma gondii from clinical specimens. The identification aids in the diagnosis of toxoplasmosis caused by the parasitic protozoan Toxoplasma gondii and provides epidemiological information on this disease. Congenital toxoplasmosis is characterized by lesions of the central nervous system, which if undetected and untreated may lead to brain defects, blindness, and death of an unborn fetus. The disease is characterized in children by inflammation of the brain and spinal cord.
Predicate Devices
- Bio-Rad Laboratories Platelia® Toxo IgG (K89497)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo for Bio-Rad Laboratories, a company that manufactures and distributes products for the life science research and clinical diagnostics markets. The logo is in black and white, with the words "BIO-RAD" in bold, sans-serif font. The logo is simple and recognizable. The logo is encased in a rounded rectangle.
SFP 3 0 2002
#### ATTACHMENT I 510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K013839
| DATE: | September 10, 2002 |
|-------------------------|------------------------------------------------------------------------------|
| APPLICANT: | Bio-Rad<br>3, Boulevard Raymond Poincaré<br>92430 Marnes-la-Coquette, France |
| OFFICIAL CORRESPONDENT: | Sylvie Confida |
| TELEPHONE: | 33-1-47-95-6138 |
| FAX: | 33-1-47-95-6242 |
| PRODUCT TRADE NAME: | Bio-Rad Laboratories Platelia® Toxo IgG TMB |
| COMMON NAME: | Toxoplasma IgG Enzyme Immunoassay (EIA) |
| CLASSIFICATION NAME: | 21 CFR 866.3780, Enzyme Linked Immunoabsorbent Assay,<br>Toxoplasma Gondii |
| PREDICATE DEVICE: | Bio-Rad Laboratories Platelia® Toxo IgG (K89497) |
#### DEVICE DESCRIPTION
The Platelia® Toxo IgG TMB assay utilizes a solid-phase enzyme immunoassay technique referred to as an indirect ELISA. Diluted test samples are placed into the T. gondii antigen coated wells of the microplate. During incubation, T. gondii antibodies present in the test sample bind to the T. gondii antigen. After incubation, unbound antibodies and other serum proteins are removed by washing. The conjugate (peroxidase-labeled monoclonal antibody specific for human gamma chains) is added to the micropalte wells. During a second incubation, the labeled monoclonal antibody binds to the IgG antibody – T. gondii antigen complexes attached to the microplate wells. The unbound conjugate is removed by washing. The addition of peroxidase substrate and chromogen solutions initiates a color development reaction. The enzymatic reaction is stopped by addition of an acid. The optical density reading, obtained with a spectrophotometer set at 450nm, is proportional to the amount of T. gondii IgG antibody present in the test sample and is converted into IU/ml using a standard curve. Standard control sera are calibrated against the WHO standard (TOXM185).
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the logo for Bio-Rad Laboratories, a company that manufactures and distributes products for the life science research and clinical diagnostics markets. The logo is black and white and features the company name in a bold, sans-serif font. The letters are large and easy to read, and the logo has a simple, modern design. The logo is often used on the company's products, website, and marketing materials.
### INTENDED USE
The Platelia® Toxo IgG TMB kit is an in-vitro diagnostic test kit for the qualitative and quantitative detection of anti-Toxoplasma gondii IgG in human serum or plasma (EDTA, Heparin, Citrate).
Note: The Platelia® Toxo IgG TMB assay has not been cleared/approved by the FDA for blood/plasma donor screening.
# TECHNOLOGICAL CHARACTERISTICS
The Platelia® Toxo IgG TMB kit is a modified version of the Platelia® Toxo IgG kit and remains similar in form and function. The following comparison table indicates significant similarities and differences between the kits:
| Characteristics | Platelia® Toxo IgG (Predicate) | Platelia® Toxo IgG TMB |
|------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Format and Test Method | 96-well microplate EIA,<br>non-breakaway wells | 96-well microplate EIA,<br>breakaway wells |
| Intended Use | Assay for the qualitative and<br>quantitative detection of anti-<br><i>Toxoplasma gondii</i> IgG in human<br>serum | Assay for the qualitative and<br>quantitative detection of anti-<br><i>Toxoplasma gondii</i> IgG in human<br>serum or plasma |
| Positive Calibrators | Pooled human serum, negative<br>for <i>T. gondii</i> , is used to dilute the<br>positive calibrators | A synthetic matrix consisting of<br>Tris-NaCl buffer, BSA, glycerol,<br>and colorant is used to<br>manufacture the negative control<br>and to dilute the positive control. |
| Chromogen | <i>o</i> . phenylenediamine-2 HCL<br>(OPD) tablets | Tetramethylbenzidine (TMB)<br>solution |
| Wavelength | Dual wavelength reading at<br>492 nm and 620 nm. | Dual wavelength reading at<br>450 nm and 620 nm |
Comparison Table
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the logo for Bio-Rad Laboratories. The logo is in black and white, with the words "BIO-RAD" in bold, sans-serif font. The letters are white, and the background is black. The logo is enclosed in a rounded rectangle.
# PERFORMANCE SUMMARY
#### A. Precision Studies
Inter-assay and intra-assay reproducibility were determined by assaying two T. gondir lgG negative samples and four T. gondii IgG positive samples in triplicate, on three different days at three laboratory sites.
| Site |
|------|
|------|
| | Neg 1 | | Neg 2 | | Pos 1 | | Pos 2 | | Pos 3 | | Pos 4 | |
|---------------------------------|-------|-------|-------|-------|-------|--------|-------|--------|-------|--------|-------|---------|
| | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N= | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean= | 0.116 | N/A | 0.073 | N/A | 1.016 | 37.544 | 0.829 | 27.144 | 1.472 | 72.500 | 2.152 | 220.222 |
| Within Run<br>(intra-assay) sd= | 0.011 | N/A | 0.005 | N/A | 0.069 | 3.871 | 0.026 | 1.375 | 0.061 | 12.670 | 0.061 | 12.936 |
| %CV= | 9.2% | N/A | 6.6% | N/A | 6.8% | 10.3% | 3.1% | 5.1% | 4.1% | 17.5% | 2.8% | 5.9% |
| Total<br>(inter-assay) sd= | 0.009 | N/A | 0.004 | N/A | 0.060 | 3.216 | 0.021 | 1.229 | 0.053 | 10.454 | 0.060 | 13.070 |
| %CV= | 7.6% | N/A | 5.6% | N/A | 5.9% | 8.6% | 2.6% | 4.5% | 3.6% | 14.4% | 2.8% | 5.9% |
Site 2
| | Neg 1 | | Neg 2 | | Pos 1 | | Pos 2 | | Pos 3 | | Pos 4 | |
|-------------------|-------|-------|-------|-------|-------|--------|-------|--------|-------|--------|-------|---------|
| | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N= | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean= | 0.134 | | 0.083 | | 0.955 | 30.522 | 0.728 | 17.733 | 1.438 | 74.489 | 2.059 | 229.378 |
| Within Run | | | | | | | | | | | | |
| (intra-assay) sd= | 0.007 | | 0.007 | | 0.010 | 0.631 | 0.024 | 1.107 | 0.020 | 2.835 | 0.031 | 9.941 |
| %CV= | 4.9% | N/A | 9.0% | N/A | 1.1% | 2.1% | 3.3% | 6.2% | 1.4% | 3.8% | 1.5% | 4.3% |
| Total | | | | | | | | | | | | |
| (inter-assay) sd= | 0.016 | | 0.012 | | 0.073 | 2.492 | 0.062 | 2.124 | 0.097 | 9.374 | 0.060 | 20.109 |
| %CV= | 11.7% | | 14.8% | | 7.7% | 8.2% | 8.5% | 12.0% | 6.8% | 12.6% | 2.9% | 8.8% |
Site 3
| | Neg 1 | | Neg 2 | | Pos 1 | | Pos 2 | | Pos 3 | | Pos 4 | |
|---------------------------------|-------|-------|-------|-------|-------|--------|-------|--------|-------|--------|-------|---------|
| | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N= | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean= | 0.231 | | 0.135 | | 1.324 | 49.875 | 0.968 | 32.000 | 1.614 | 99.889 | 2.560 | 240.000 |
| Within Run<br>(intra-assay) sd= | 0.011 | | 0.022 | | 0.065 | 3.682 | 0.040 | 2.000 | 0.068 | 15.899 | 0.171 | 0.000 |
| %CV= | 4.7% | N/A | 16.1% | N/A | 4.9% | 7.4% | 4.1% | 6.3% | 4.2% | 15.9% | 6.7% | 0.0% |
| Total<br>(inter-assay) sd= | 0.012 | | 0.028 | | 0.104 | 6.935 | 0.114 | 8.775 | 0.256 | 40.746 | 0.161 | 0.000 |
| %CV= | 5.3% | | 21.1% | | 7.8% | 13.9% | 11.8% | 27.4% | 15.9% | 40.8% | 6.3% | 0.0% |
N/A = Not applicable
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for Bio-Rad. The logo is in white text on a black, rounded rectangle. The text is bold and slightly slanted.
In addition, inter-assay and intra-assay reproducibility with plasma samples were determined by assaying three additional samples (one T. gondii IgG negative sample and two T. gondii IgG positive samples) in triplicate, on three different days, at one laboratory site.
| Serum | Neg 1 | | Pos 1 | | Pos 2 | |
|--------------------|-------|-------|-------|-------|-------|-------|
| | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N = | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean = | 0.061 | | 0.918 | 29.37 | 0.735 | 19.98 |
| Within-Run | | | | | | |
| (intra-assay) sd = | 0.003 | | 0.043 | 2.242 | 0.018 | 0.930 |
| %CV = | 4.9% | N/A | 4.7% | 7.6% | 2.4% | 4.7% |
| Total | | | | | | |
| (inter-assay) sd = | 0.002 | | 0.098 | 2.936 | 0.052 | 1.131 |
| %CV = | 4.1% | | 10.7% | 10.0% | 7.0% | 5.7% |
| EDTA | Neg 1 | | Pos 1 | | Pos 2 | |
| | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N = | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean = | 0.047 | | 0.909 | 28.83 | 0.672 | 16.73 |
| Within-Run | | | | | | |
| (intra-assay) sd = | 0.003 | | 0.050 | 2.555 | 0.041 | 2.197 |
| %CV = | 6.7% | N/A | 5.5% | 8.9% | 6.1% | 13.1% |
| Total | | | | | | |
| (inter-assay) sd = | 0.004 | | 0.099 | 3.017 | 0.049 | 1.839 |
| %CV = | 8.1% | | 10.9% | 10.5% | 7.3% | 11.0% |
| Citrate | Neg 1 | | Pos 1 | | Pos 2 | |
| | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N = | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean = | 0.067 | | 0.918 | 29.30 | 0.735 | 19.93 |
| Within-Run | | | | | | |
| (intra-assay) sd = | 0.003 | | 0.019 | 0.981 | 0.015 | 0.739 |
| %CV = | 4.3% | N/A | 2.1% | 3.3% | 2.0% | 3.7% |
| Total | | | | | | |
| (inter-assay) sd = | 0.004 | | 0.072 | 1.373 | 0.063 | 1.602 |
| %CV = | 6.3% | | 7.8% | 4.7% | 8.6% | 8.0% |
| Heparin | Neg 1 | | Pos 1 | | Pos 2 | |
| | OD | IU/ml | OD | IU/ml | OD | IU/ml |
| N = | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean = | 0.060 | | 0.910 | 28.89 | 0.714 | 18.91 |
| Within-Run | | | | | | |
| (intra-assay) sd = | 0.010 | | 0.015 | 0.805 | 0.037 | 1.877 |
| %CV = | 16.7% | N/A | 1.7% | 2.8% | 5.1% | 9.9% |
| Total | | | | | | |
| (inter-assay) sd = | 0.008 | | 0.095 | 2.651 | 0.050 | 1.596 |
N/A = Not applicable
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for BIO-RAD. The logo is white text on a black rounded rectangle. The text is bold and sans-serif.
#### B. Comparison Studies
Performance of the Platelia® Toxo IgG TMB assay was evaluated against another commercially available enzyme immunoassay (EIA) by testing 468 prospective samples and 35 retrospective specimens from 11 seroconversion panels.
| N = 503 | | TMB | | |
|---------|-----------|-----|-----------|-----|
| | | Neg | Equivocal | Pos |
| O | Neg | 339 | 5 | 1 |
| P | Equivocal | 0 | 3 | 3 |
Platelia® Toxo IgG TMB vs OPD Correlation Table (combined results)
Excluding equivocal samples, the combined results of comparative and retrospective testing demonstrated the following :
Negative agreement : 99.71% (339/340). The 95% confidence interval6 is 98.98% - 100.00%.
Positive agreement : 100.00% (149/149). The 95% confidence interval40 is 99.66% - 100.00%.
Overall agreement : 99.80% (488/489). The 95% confidence interval16 is 99.29% - 100.00%.
#### C. Expected Values
| D
A total of 503 fresh and frozen serum samples obtained from pregnant women during routine laboratory activities in the area of Paris, France were tested with the Platelia® Toxo IgG TMB assay. The distribution of IU/ml values is shown in the following chart.
Image /page/4/Figure/11 description: The image is a bar graph titled "Platelia Toxo IgG TMB Expected Values". The x-axis is labeled "Titer (IU/ml)" and displays titer ranges, while the y-axis is labeled "Frequency". The bar graph shows the frequency of different titer ranges, with the highest frequency of 332 occurring in the <3 range.
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the logo for Bio-Rad Laboratories. The logo is white text on a black rounded rectangle. The text is in a bold, sans-serif font.
#### D. CDC Test Panel
The following information is from a serum panel obtained from the CDC and tested by Bio-Rad Laboratories. The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This docs not imply an endorsement of the assay by the CDC.
The panel consists of 70 positive and 30 negative samples. The Platelia® Toxo IgG TMB assay demonstrated 100% agreement with the positive specimens and 100% agreement with the negative specimens.
Please Note: There should be no other statistical calculation or inferences drawn from the panel results.
{6}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized caduceus-like symbol with three curved lines emanating from a central point, resembling a stylized human figure. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol.
Food and Drug Administration 2098 Gaither Road · Rockville MD 20850
# SEP 3 0 2002
Mr. David Bhend Regulatory Affairs Associate Bio-Rad Laboratories Diagnostics Group 6565 18511 Avenue NE Redmond, WA 98052
Re: k013839
> Trade/Device Name: Platelia® Toxo IgG TMB Regulation Number: 21 CFR 866.3780 Regulation Name: Toxoplasma gondii serological reagents Regulatory Class: Class II Product Code: LGD Dated: July 19, 2002 Received: July 23, 2002
Dear Mr. Bhend:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{7}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and i additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device. please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{8}------------------------------------------------
Bio-Rad Laboratories Platelia Toxoplasma IgG TMB EIA
ATTACHMENT G
510(k) Number (if known): K013839
Device Name: Platelia® Toxo IgG TMB
# Indications for Use:
The Platelia® Toxo IgG TMB kit is an in-vitro diagnostic test kit for the qualitative and quantitative detection of anti-Toxoplasma gondii IgG in human serum or plasma (EDTA, Heparin, Citrate).
Note: The Platelia® Toxo IgG TMB assay has not been cleared/approved by the FDA for blood/plasma donor screening.
(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)
# Concurrence of CDRH, Office of Device Evaluation (ODE)
Professional Use:
OR
Prescription Use: (Per 21 CFR 801.109)
Over-The-Counter Use: (Optional Format 1-2-96)
09)
Alfred Aubain
510(k) Number
